Published in

Wiley, Alimentary Pharmacology and Therapeutics, 5(30), p. 444-451, 2009

DOI: 10.1111/j.1365-2036.2009.04055.x

Links

Tools

Export citation

Search in Google Scholar

Clinical trial: Low plasma cholesterol and oxidative stress predict rapid virological response to standard therapy with peginterferon and ribavirin in HCV patients

Journal article published in 2009 by Francesco Angelico, S. Francioso, Maria Del Ben, K. Feole, M. Carbone, Pasquale Pignatelli, Francesco Violi ORCID, Mario Angelico
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Orange circle
Postprint: archiving restricted
Upload
Red circle
Published version: archiving forbidden
Policy details
Data provided by SHERPA/RoMEO

Abstract

P>Background Rapid virological response (RVR) is the best predictor of sustained response to standard HCV treatment. Aim To evaluate predictive factors of RVR. Methods Sixty-five patients (mean age 52.6 +/- 13.8; 37 genotype-1, and 28 genotypes-2/3) were consecutively treated with pegIFN-alpha2a or 2b once weekly plus daily ribavirin based on body weight for 24 or 48 weeks, according to genotype. RVR was defined as undetectable HCV-RNA at week 4. Results Twenty-seven percent of patients achieved RVR in genotypes 1 and 60.7% in genotypes 2/3 (P